Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Delmar Pharmaceuticals Inc (DMPI)

Delmar Pharmaceuticals Inc (DMPI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,290
  • Shares Outstanding, K 2,654
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,050 K
  • 60-Month Beta 1.25
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.36
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/12/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.40
  • Number of Estimates 1
  • High Estimate -0.40
  • Low Estimate -0.40
  • Prior Year -0.90
  • Growth Rate Est. (year over year) +55.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.40 +20.90%
on 10/14/19
0.63 -22.61%
on 09/19/19
-0.13 (-20.98%)
since 09/18/19
3-Month
0.40 +20.90%
on 10/14/19
2.66 -81.73%
on 07/24/19
-0.86 (-64.00%)
since 07/18/19
52-Week
0.40 +20.90%
on 10/14/19
7.00 -93.06%
on 10/23/18
-6.01 (-92.52%)
since 10/18/18

Most Recent Stories

More News
DelMar Pharmaceuticals to Present at the Inaugural MicroCap Rodeo Investor Conference on October 15, 2019 at 11:30 AM Central Time

DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced that Mr. Saiid Zarrabian, Chief Executive...

DMPI : 0.49 (-6.29%)
DelMar Pharmaceuticals to Present at the Fall Investor Summit on September 16, 2019

DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today announced that CEO Saiid Zarrabian will...

DMPI : 0.49 (-6.29%)
DelMar Pharmaceuticals Announces Fiscal Year 2019 Financial Results and Recent Corporate Updates

DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the year ended...

DMPI : 0.49 (-6.29%)
DelMar Pharmaceuticals Reports Full Compliance with Nasdaq Listing Criteria

DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today announced that on September 6, 2019, the...

DMPI : 0.49 (-6.29%)
DelMar Pharmaceuticals Relocates Headquarters to San Diego, California

DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today announced that the Company has relocated...

DMPI : 0.49 (-6.29%)
DelMar Pharmaceuticals Anticipates Current Cash Runway Will Provide Sufficient Capital for Full Enrollment in All Three Patient Groups in Two Phase 2 Clinical Trials

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today announced that the Company anticipates that...

DMPI : 0.49 (-6.29%)
Thinking about buying stock in Aurora Cannabis, American Express, Walt Disney Co, DelMar Pharmaceuticals, or Tilray?

InvestorsObserver issues critical PriceWatch Alerts for ACB, AXP, DIS, DMPI, and TLRY.

AXP : 116.76 (-1.96%)
ACB.TO : 4.81 (-5.87%)
DMPI : 0.49 (-6.29%)
DIS : 130.89 (-1.12%)
DelMar Pharmaceuticals Announces Pricing Of $6.8 Million Underwritten Public Offering

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today announced the pricing of an underwritten...

DMPI : 0.49 (-6.29%)
DelMar Pharmaceuticals Reports Updated Results on Twenty Patients from the Phase 2 Clinical Trial of VAL-083 as First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, provided an update on the first 20 patients enrolled...

DMPI : 0.49 (-6.29%)
DelMar Pharmaceuticals Achieves Two-Thirds Enrollment for Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today announces it has achieved two-thirds enrollment...

DMPI : 0.49 (-6.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade DMPI with:

Business Summary

DelMar Pharmaceuticals, Inc. is involved in developing drug for orphan cancer indications. DelMar Pharmaceuticals, Inc. is headquartered in Vancouver, Canada.

See More

Key Turning Points

2nd Resistance Point 0.56
1st Resistance Point 0.52
Last Price 0.49
1st Support Level 0.47
2nd Support Level 0.45

See More

52-Week High 7.00
Fibonacci 61.8% 4.48
Fibonacci 50% 3.70
Fibonacci 38.2% 2.92
Last Price 0.49
52-Week Low 0.40

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar